Leon-nanodrugs GmbH is a nanotechnology-based drug development company focused on reformulations and reinventions of drugs on a contract or co-development basis. The company designs and develops oral and parenteral formulations and drug combinations using good manufacturing practice compliant nanotechnology to improve bioavailability, solubility, and dissolution rates. Its products include active pharmaceutical ingredients, such as small molecules, proteins, peptides, hormones, and vaccines; and nanoparticles and drug-delivery-systems, including nanoparticles, polymer coated API nanoparticles, multilayer nanoparticles, functionalized multilayer nanoparticles, polymer nanoparticles functionalized with API, polymer nanoparticles with API molecules on the surface and in the particle, nanoemulsions, and coated nanoemulsions. The company also offers conception and consulting, regulatory clearance, feasibility, patent research/formulation and submission, biological profiling, technical development, clinical trials, documentation, technology transfer, and project management services for its customers. It offers formulations in the form of tablets, capsules, liquids, and medical chewing gums. Leon-nanodrugs GmbH was founded in 2010 and is based in Munich, Germany.